INTRODUCTION
============

Acute coronary syndrome (ACS) is a common manifestation of cardiovascular disease and its recognition with appropriate treatment impacts patient mortality and morbidity \[[@R1]\]. To date, there are no data on one-year outcomes of unselected Middle East Gulf citizens with ACS. The main aims of Gulf COAST were to: a) determine the clinical risk profiles of citizens with ACS, b) describe the practice of physicians involved in the care of ACS patients, and determine the level of adherence to evidence-based guidelines, c) determine patient reported behavioral changes after ACS (e.g. smoking cessation, adoption of exercise, return to work and return to pre-illness sexual activity), and, d) describe 12 months morbidity and mortality outcomes for these patients.The results will provide valuable insight to identify care gaps for healthcare providers and policy makers in the region, and act as foundation for future quality improvement initiatives.

MATERIALS AND METHODOLOGY
=========================

Registry Design
---------------

The Gulf COAST registry is a prospective, multinational, longitudinal, observational, cohort-based survey of all consecutive citizens who were admitted to hospitals with a confirmed diagnosis of ACS. Enrolment started in January 2012 and ended in January 2013. The Ethics Committees of each participating institution or country approved the study protocol.The current report presents the registry's design, methodology, rationale, protocol implementation and patients' baseline characteristics. The Gulf COAST registry adhered to the recommendations of "Strengthening the Reporting of observational studies in Epidemiology (STROBE)" \[[@R2]\].

Participating Hospitals
-----------------------

To provide findings that are representative of the involved countries, \> 85% of the general hospitals in each country were included. The registry recruited patients from 29 hospitals in 4 Middle East Gulf countries: Kingdom of Bahrain (Bahrain): 2; State of Kuwait (Kuwait): 6; Sultanate of Oman (Oman): 12; and United Arab Emirates (UAE): 9.Of the 29 participating hospitals, 14 were community hospitals, 18 non-university teaching hospitals and 1 private sector hospital. All of the hospitals had on-site thrombolytic therapy available. On-site cardiac catheterization was available in 9 of the hospitals, while another 10 had a cardiac catheterization laboratory available to them within 1 h drive.

Administrative Organization and Hierarchy
-----------------------------------------

Asteering committee from regional experts in the field was formed. A registry manager was appointed to coordinate between the national coordinators (NC), chief site officers (CSO) and site officers (SO) in the 4 countries. The protocol and the case report form (CRF) were drafted by the primary investigator and the study manager, and reviewed by the steering committee. Prior to the commencement of enrolment, one steering committee meeting and one investigators meeting were held. In addition, country-level and hospital-level meetings were held by the NCs in their respective countries. These meetings involved CSOs and SOs to educate them about the protocol and CRF. The CSOs supervised recruitment to ensure it was consecutive and helped answer data queries generated for their sites. The SOs recruited patients, and filled out CRFs prospectively at admission time and during hospital. Later on, they transferred the data online at their earliest convenience either from the workplace or other locations, depending on whether or not internet service was available at the hospital.

Study Population
----------------

Patients enrolled in the registry were citizens, 18 years of age or older with ACS diagnosed according to American College of Cardiology (ACC) clinical data standards \[[@R3]\].The decision to enroll citizens only was determined by the need to have near complete follow up of the study population.The expatriate population come from different countries, they are young, mostly male and highly mobile. This made it hard to guarantee their availability for follow up at 1 year. In addition, citizens are relatively homogenous in terms of their lifestyle, standard of living and access to free universal health care. There were no other exclusion criteria, and an attempt was made to recruit all comers. Patients were enrolled only after obtaining written informed consent to participate in the study. Patients who were eligible for inclusion in the registry but were not recruited for any reason (e.g. refused consent, died before consent) were entered into log sheets that recorded their age, gender, diagnosis and reason for not beingenrolled.

Data Collection and Validation
------------------------------

Data were prospectively collected on a standardized case report form (CRF). Data variables were in accordance with ACC key data elements and definitions for measuring the clinical management and outcomes of patients with ACS \[[@R3]\]. Data collected included patient demographics, previous diseases and risk factors, prior medication,clinical presentation, management during hospital stay including medications, reperfusion therapy and procedures, outcomes and discharge medications and follow up arrangements. Follow up was planned at 1, 6 and 12 months from the date of enrolment. Follow up was carried out by clinic visit or telephone interview. Data entry was carried out by SOs online at www.gulfcoastregistry.org**.**

A feature of the online data entry system included immediately-displayed automated data checks for out-of-range values and missing values of single data fields and also contradictory entries related to multiple data fields. In addition, throughout and at the conclusion of the study,to ensure accuracy of data, the registry manager carried out data cleaning using IBM® SPSS® Statistics 19 Program. A clinical research associate carried out site visits which included a visit to all participating hospitals at least once and involved random data source verification of 10% of paper and electronic CRFs at each visit.

Sample Size
-----------

In determining the sample size for Gulf COAST, we considered practical and statistical inputs. Practically, we weighed both logistical and funding issues including the number of citizens with ACS we expect to enroll from the participating centres over the planned enrolment phase.This was informed by prior experience with a large ACS registry of all comers in the Gulf Registry of Acute Coronary Events (Gulf RACE), where approximately 2500 local patients with ACS were enrolled over a 6-month period \[[@R4]\]. Hence, we can expect to comfortably enroll \~ 5,000 patients from the same centers over a 12-month enrolment period. Statistically, we recognize the difficulty in estimating sample size in an observational registry where several variables will be measured and no primary comparisons are planned. Nonetheless, we wanted to ensure adequate precision in the estimate of one-year all-cause mortality among locals presenting with ACS. To estimate an annual mortality rate of 10% at 1 year with a margin of error of 1% and 95% confidence intervals, a sample size of 2,948 patients is required. However, since there is little guidance in the literature on annual mortality of Gulf citizens with ACS, and also to compensate for losses of follow-up, we adjusted our sample size upwards to 4,000 patients.

As shown in Fig. (**[1](#F1){ref-type="fig"}**), a sample size of 4,000 will provide adequate precision in estimating annual mortality over a reasonably wide range of event rates, and is logistically feasible given our prior experience \[[@R5]\]. We also considered the precision of all-cause mortality estimates for the following subgroups: ST-segment elevation myocardial infarction (STEMI), women, and patients younger than 50 years. Based on observations from Gulf RACE \[[@R5]\]. We estimate that 20% of citizens with ACS will have STEMI, 40% will be women, and 25% will be younger than 50 years. Therefore, for a total sample size of 4,000 patients with ACS, we expect 800 patients with STEMI, 1600 women, and 1000 patients younger than 50 years. These numbers will allow us adequate precision around all-cause mortality estimates for these subgroups with at least 90% confidence and, at most, 2% margin of error.

Statistical Analysis
--------------------

Baseline hospital and patient characteristics were summarized using standard descriptive statistics.Continuous variables were summarized using means and standard deviations, where the distributions were normal or near normal, or medians and 25th/75th percentiles otherwise. Categorical variables were summarized using percentages.

RESULTS
=======

Study Population Characteristics
--------------------------------

Of 3188 patients, 1194 (37.5%) were recruited from Oman, 975 (30.5%) from Kuwait, 610 (19%) from UAE and 409 (13%) from Bahrain. The distribution of discharge diagnoses were as follows: non-ST-segment elevation myocardial infarction (NSTEMI): 1486 (46.6%), unstable angina: 931 (29.2%), STEMI: 741 (23.2%) and new-onset left bundle branch block myocardial infarction: 30 (0.9%). The mean age was 60.4 ± 12.8 years. Table **[1](#T1){ref-type="table"}** shows the patients' characteristics.

The population risk profile included hypertension: 66%, dyslipidemia: 55.8%, diabetes mellitus: 53.4% and current smoking: 23.2% (Table **[2](#T2){ref-type="table"}**).

At presentation, the mean heart rate was 85.6 ± 21.3 beats/min, mean systolic blood pressure was 141.3 ± 28.2 mmHg and mean diastolic blood pressure was 80.7 ± 16.5 mmHg. Three-quarters of the patients were over weight or obese (Table **[3](#T3){ref-type="table"}**).

Non-Participation
-----------------

A total of 151 patients fulfilled the entry criteria but were not enrolled in the registry because of a refusal to consent:

LBBB MI: left bundle branch block myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; GPIIb/IIIa inhibitor: glycoprotein IIb/IIIa inhibitor.

TIA = transient ischemic attack; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft. 89 patients (59%) or not being approached by investigators: 62 patients (41%). Per country, the failure to enroll was 1.5% for Bahrain, 3.2% for Oman, 6.4% for Kuwait and 7% for UAE.

DISCUSSION
==========

The Gulf COAST registry is the first prospective registry from the region focusing on citizens suffering from ACS with a planned long-term follow up. The baseline characteristics of citizens with ACS in the Gulf region of the Middle East were described in this report. The age of our patients was much younger compared to published Western data \[[@R6],[@R7]\]. Nevertheless, we found they had high cardio-metabolic risk burden in the form of overweight and obesity, diabetes mellitus, hypertension and smoking.

Registries have fewer exclusion criteria and consequently include a wider range of patients. Therefore, observational prospective patient registries like ours complement randomized trials by providing evidence derived from a different type of study methodology \[[@R8]\]. Compared to randomized trials, well-conducted registries have the benefit of providing a representative "real-world" view of both clinical practice and patient outcomes provided that investigators ensure high-quality data with clear vision regarding the strengths and weaknesses of the registry being conducted \[[@R9]\]. The current registry will enhance our knowledge regarding ACS medical practices in the region in several ways. First,advances in practice made in 2012 can be compared with previous practice from 2007 \[[@R5]\]. This will encompass many practice patterns, importantly the degree of adoption of primary percutaneous coronary intervention (PCI) in patients with acute STEMI. Second, it will provide important information about long-term outcomes of patients with ACS in the region. Third, Gulf COAST will, for the first time, provide data on social and lifestyle behavior of Gulf citizens after an ACS. Fourth, we plan to focus on the influence of risks such as diabetes and obesity that are common in our patients. Finally, the registry will enable us to compare practices between the 4 participating countries and its influence on outcomes, especially comparing the practice in Oman, a large country with lower annual individual income compared with the other 3 countries.

Implications of the Registry
----------------------------

We believe the subsequent analysis of all data and future publications from Gulf COAST will contribute to the existing literature and will contribute to better management of the ACS patient in the Gulf. We hope data from Gulf COAST would inform health care policy in the region and guide providers and regulatory authorities in their decisions regarding local and regional policy for cardiovascular care, from prevention to management and subsequent guideline construction. The data will provide local authorities with an insight into their local shortcomings which can translate into a quality improvement programs and policies.

Study Limitations and Strengths
-------------------------------

As with any observational study, the execution of the registry may be limited by selection bias, particularly the potential exclusion of high-risk patients. In order to minimize this bias, we introduced a log sheet that investigators complete for all patients who were not enrolled. Moreover, we acknowledge that citizenship and ethnicity are not synonymous. Hence, while citizens may have relatively homogeneous lifestyle and social status, there may be some ethnic heterogeneity that we did not account for. The strength of our registry comes from its design that included 4 different countries, participation of the majority of hospitals in each country and enrolment of all patients presenting to each hospital.
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APPENDIX
========

Gulf COAST Administrative Organization
--------------------------------------

***Steering Committee:***Mohammad Zubaid (Principal Investigator, steering committee chairman, Kuwait), Wafa Rashed (Registry manager, National Coordinator, Kuwait), Mustafa Ridha (Kuwait), Fahad Alenezi (Kuwait), Rashid Alhamdan (Kuwait), Mousa Akbar (Kuwait), Najib Alrawahi (National Coordinator, Oman), Haitham Amin (National Coordinator, Bahrain), Wael Almahmeed (UAE), Alawi Alsheikh-Ali (Registry statistician, UAE), Abdullah Shehab (National Coordinator, UAE), Husam Ouda (UAE), Abdullah Alnuaimi (UAE), Fahad Baslaib (UAE), Arif Al-Mulla (UAE) and Harlan Krumholz (USA).

Investigators:
--------------

***Bahrain:**Bahrain Defense Hospital:*Leena Sulaibikh\*, Babu Thevan, Dev Sheel, Fahimuddin Sayed, Fawaz Bardooli, Hugmi Jain, Jasim Mohammed, Manal Matar, Rajesh Jayakumar, Sanjeev Kumar Jaiswal, S Mushtaq Sayed, Vinayak Vadgaonkar. *Salmaniya Medical Complex***:**Taysir Garadah\*, Khalid Bin Thani\*, Aisha Al-Moosa, Alaa Al-Zamrooni, Mohamed E. Alalawi, Eman Murad, Fajer Al-Moosa, Aziza Matooq.

***Kuwait:**Adan Hospital:*Sadiq Abdul\*, Abdel aleem Rabie, Ahmed Nabil Hassan, Ahmed El Mugharbil, Sherif Arafat. *Ahmadi (Kuwait Oil Company) Hospital: Shahid Zubair*\* *Chest Hospital:*Medhat Soliman\*, Mohamed Farouk Elkhalifa, Mohamed Ali Sallam, Viji Koshy George. *Farwaniya Hospital:* Amr Elguindy\*, Ahmed Amin, Ayman Abdel Mawgoud, Emad Nashaat, Mahmoud Abdel Tawab, MiladRafla, Mohamed Okba, Mousa Arafat. *Jahra Hospital:*Mohammad El Gindy\*, Melek Atta, Mustafa Alshaikha, Rim Ahmed. *Mubarak Hospital:* Ibrahim Farrag\*, Abdulmonem Mohamad, Ashraf Hammad, FawzyMaqlad, GladisHefny, Hani Bassiouny, IhabAwwad, Maged Youssef, Motaz Elarini, Nabil Ragab, SamehElmasry, Samir Mohamad. *Sabah Hospital:* Islam Elsisy\***,**Mahmoud Korashy**,**Simon George.

***Oman:**Armed Force Hospital:*BR Kamath\*, Bichu Ruchir Kumar. *Bahala Hospital:* Kurian Mathew\*. *Burami Hospital:*Naguib Asham Zaki\*. *Ibri Hospital:*BimalChakroborty\*, Abdalla Abdalla, Ayman Aziz, Nipa Saha, Yaseer Khan. *Nizwa Hospital:*Mourad Al Sharkawy\*, Abdel-Salam Gamil, Abubaker Ahmed, Ahmed Abdulla Elamin, Ahmed Nidham Nidham, Amjad Saeed Merghani Hammour, Azhar Al-shaibany, Bahaa Eldin Mohamed, Fahmy Hilal, Imadeldin Mohammed Alhaj, Mahmud Hassan, Mohamed Ebrahime, Sabah Al Saeedi, Emad Salah Fathy, Ahmed Hegazy. *Royal Hospital:* Mohamed Al-Riyami\*, Amir Al-Amri\*, Wadhha Alsiyabi, Hany Samir. *Royal Police Hospital:* Abdul Malik\*, Renchi Mathew. *Rustaq Hospital:* Osama Alkadi\*, AlaaElmeligy, Mian Nasirud Din. *Sohar Hospital:*Aouf Mohamad Alazzawi \*, Ali Al-Khafaji, Hamada Mohamed Amin, Hatim Issa, Jan Gorgy, Mohamed Abdulraheem, Salma Jabeen, Sameh Girgis, Sheshadri Pasupathy. *Sur Hospital:*Qassim Shimal\*, Ganesh Vimal, *Sumail Hospital:*Safwat Abdel Wahab\*, Ahmed Mosad Ibrahim, Manal Sabry Mohamed. *Sultan Qaboos Salalah Hospital:*Prit pal Singh\*.

***United Arab Emirates:**Dubai Hospital:*Nooshin Bazargani\*, Arif Abdullatif AlMulla\*, Sadek Ali. *Fujairah Hospital:*Amrish Agrawal\* *Khorfakan Hospital:*Magda Helal\* *Qasimi Hospital:*Wael Al Abbasi\*, Loai Abu Mousa\*, Ruwaida Najeeb. *Ras Al Khaima Hospital:*Adel Wassef\* *Rashid Hospital:*Khalifa Omar Muhammed\*, Amr Moustafa\*, Ali Raza Rajani, Khalifa Muhammed, Mohamed Al-Raqabani, Shibu Bahuleyan. *Sheikh Khalifa Medical City (SKMC):* Masood Ghori\*, Amer Sana, Hamdy Mohamed. *Tawam Hospital:*Sadek El Mokahal**\***, Amany Hillis**,**Mohammed Nour Mustafa**,**Teena Abdalla. *Zayed Military Hospital:*Zubair Memon\*

\*Chief site officer
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###### 

Baseline characteristics of patient population.

  **Characteristics**                      **n = 3188**
  ---------------------------------------- --------------
  Male gender, n (%)                       2108 (66.1)
  Age, mean ± SD (years)                   60.4±12.6
  Age category (years)                     
  \<45, n (%)                              344 (10.8)
  45-54, n (%)                             701 (22)
  55-74, n (%)                             1732 (54.3)
  ≥75, n (%)                               411 (12.9)
  Means of transport                       
  Ambulance, n (%)                         789 (24.7)
  Self/Family/Friend, n (%)                2399 (75.3)
  Presenting symptoms                      
  Typical pain, n (%)                      2406 (75.5)
  Atypical pain, n (%)                     141 (4.4)
  Dyspnea, n (%)                           220 (6.9)
  Dyspnea and ischemic pain, n (%)         310 (9.7)
  Other, n (%)                             111 (3.5)
  Cardiac arrest on admission, n (%)       58 (1.8)
  Non-cardiac condition, n (%)             82 (2.6)
  Killip Class                             
   I, n (%)                                2452 (76.9)
   II, n (%)                               450 (14.1)
   III, n (%)                              251 (7.9)
   IV, n (%)                               35 (1.1)
  Medication prior to admission            
  Aspirin, n (%)                           1905 (59.8)
  Clopidogrel, n (%)                       667 (20.9)
  Warfarin, n (%)                          61 (1.9)
  Beta-Blocker, n (%)                      1440 (45.2)
  ACE inhibitor, n (%)                     1239 (38.9)
  ARB, n (%)                               474 (14.9)
  Statin, n (%)                            1923 (60.3)
  Medications received in the first 24 h   
  Aspirin, n (%)                           3132 (98.2)
  Clopidogrel, n (%)                       2478 (77.7)
  Anticoagulant, n (%)                     2681 (84.1)
  GPIIb/IIIa inhibitor, n (%)              208 (6.5)
  Characteristics                          n = 3188
  GPIIb/IIIa inhibitor, n (%)              208 (6.5)
  Beta-Blocker, n (%)                      2477 (77.7)
   ACE inhibitor, n (%)                    2126 (66.7)
  ARB, n (%)                               414 (13)
  Statin, n (%)                            3088 (96.9)
  Intravenous insulin infusion, n (%)      398 (12.5)

LBBB MI: left bundle branch block myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; GPIIb/IIIa inhibitor: glycoprotein IIb/IIIa inhibitor.

###### 

Past medical history and CV risk factors.

  **Past medical history**         **n = 3188 n (%)**
  -------------------------------- --------------------
  Hypertension                     2105 (66)
  Dyslipidemia                     1779 (55.8)
  Diabetes mellitus                1703 (53.4)
  Current smoker                   740 (23.2)
  TIA                              83 (2.6)
  Stroke                           198 (6.2)
  Previous history of CV disease   
  Myocardial infarction            835 (26.2)
  Angina                           1242 (39)
  PCI                              668 (21)
  CABG                             237 (7.4)
  Heart Failure                    418 (13.1)
  Devices                          39 (1.2)

TIA = transient ischemic attack; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft.

###### 

Findings on physical examination at first presentation.

  ** **                          **n = 3188**
  ------------------------------ --------------
  Heart rate, mean ± SD           85.6±21.3
  Systolic BP, mean ± SD         141.3±28.2
  Diastolic BP, mean ± SD        80.7±16.5
  BMI, mean ± SD                 29.2±8.9
  BMI category                   
  ≤18.5, n (%)                   33 (1.05)
  18.5-25, n (%)                 733 (23.3)
  25-30, n (%)                   1240 (39.4)
  \>30, n (%)                    1142 (36.2)
  ECG                            
  ST-segment elevation, n (%)    737 (23.1)
  New LBBB, n (%)                32 (1)
  ST-segment depression, n (%)   800 (25.1)
  Other, n (%)                   1619 (50.7)

BP: blood pressure; BMI: body mass index; ECG: electrocardiogram; LBBB: left bundle branch block.
